These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 43165)

  • 61. Labetalol and lipids.
    McGonigle RJ; Williams L; Murphy MJ; Parsons V
    Lancet; 1981 Jan; 1(8212):163. PubMed ID: 6109848
    [No Abstract]   [Full Text] [Related]  

  • 62. Labetalol and determination of pressor hormones.
    Harvengt C
    Ann Intern Med; 1984 Feb; 100(2):314. PubMed ID: 6691680
    [No Abstract]   [Full Text] [Related]  

  • 63. Antinuclear antibodies in patients on acebutolol.
    Booth RJ; Bullock JY; Wilson JD
    Br J Clin Pharmacol; 1980 May; 9(5):515-7. PubMed ID: 6104977
    [No Abstract]   [Full Text] [Related]  

  • 64. Clinical and pharmacokinetic studies on the alpha- and beta-blocking drug labetalol.
    Kanto J; Allonen H; Lehtonen A; Mäntylä R; Pakkanen A
    Ther Drug Monit; 1980; 2(2):145. PubMed ID: 7052285
    [No Abstract]   [Full Text] [Related]  

  • 65. Pharmacology. New discoveries and the sympathetic nervous system.
    Wachs GN
    Int J Dermatol; 1973; 12(5):280-2. PubMed ID: 4147809
    [No Abstract]   [Full Text] [Related]  

  • 66. Labetalol: a review of its pharmacology, pharmacokinetics, clinical uses and adverse effects.
    MacCarthy EP; Bloomfield SS
    Pharmacotherapy; 1983; 3(4):193-219. PubMed ID: 6310529
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Labetalol and other agents that block both alpha- and beta-adrenergic receptors.
    Pearce CJ; Wallin JD
    Cleve Clin J Med; 1994; 61(1):59-69; quiz 80-2. PubMed ID: 8124849
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Labetalol.
    Carter BL
    Drug Intell Clin Pharm; 1983 Oct; 17(10):704-12. PubMed ID: 6354658
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Early lowering of blood pressure after acute intracerebral haemorrhage: a systematic review and meta-analysis of individual patient data.
    Moullaali TJ; Wang X; Sandset EC; Woodhouse LJ; Law ZK; Arima H; Butcher KS; Chalmers J; Delcourt C; Edwards L; Gupta S; Jiang W; Koch S; Potter J; Qureshi AI; Robinson TG; Al-Shahi Salman R; Saver JL; Sprigg N; Wardlaw JM; Anderson CS; Bath PM;
    J Neurol Neurosurg Psychiatry; 2022 Jan; 93(1):6-13. PubMed ID: 34732465
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Retrospective evaluation of labetalol as antihypertensive agent in dogs.
    Zublena F; De Gennaro C; Corletto F
    BMC Vet Res; 2020 Jul; 16(1):256. PubMed ID: 32709242
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effects of nitroglycerin versus labetalol on peripheral perfusion during deliberate hypotension for sinus endoscopic surgery: a randomized, controlled, double-blinded trial.
    Zayed M; Nassar H; Hasanin A; Saleh AH; Hassan P; Saad D; Mahmoud S; Abo Bakr G; Fouad E; Saleh N; Ismail M; El-Hadi H
    BMC Anesthesiol; 2020 Apr; 20(1):85. PubMed ID: 32303182
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Neurogenic hypertension: pathophysiology, diagnosis and management.
    Mann SJ
    Clin Auton Res; 2018 Aug; 28(4):363-374. PubMed ID: 29974290
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Labile and Paroxysmal Hypertension: Common Clinical Dilemmas in Need of Treatment Studies.
    Mann SJ
    Curr Cardiol Rep; 2015 Nov; 17(11):99. PubMed ID: 26370555
    [TBL] [Abstract][Full Text] [Related]  

  • 74. CYP2C19 genotype has a major influence on labetalol pharmacokinetics in healthy male Chinese subjects.
    Chan SW; Hu M; Ko SS; Tam CW; Fok BS; Yin OQ; Chow MS; Tomlinson B
    Eur J Clin Pharmacol; 2013 Apr; 69(4):799-806. PubMed ID: 23090703
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A simplified mechanistic algorithm for treating resistant hypertension: efficacy in a retrospective study.
    Mann SJ; Parikh NS
    J Clin Hypertens (Greenwich); 2012 Apr; 14(4):191-7. PubMed ID: 22458739
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The clinical spectrum of labile hypertension: a management dilemma.
    Mann SJ
    J Clin Hypertens (Greenwich); 2009 Sep; 11(9):491-7. PubMed ID: 19751461
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Psychological characteristics and responses to antihypertensive drug therapy.
    Mann SJ; Gerber LM
    J Clin Hypertens (Greenwich); 2002; 4(1):25-34. PubMed ID: 11821634
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The dose dependency of the alpha- and beta-adrenoceptor antagonist activity of carvedilol in man.
    Tham TC; Guy S; McDermott BJ; Shanks RG; Riddell JG
    Br J Clin Pharmacol; 1995 Jul; 40(1):19-23. PubMed ID: 8527263
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Circulatory and metabolic effects of a combined alpha- and beta-adrenoceptor blocker (labetalol) in hypertension of pregnancy.
    Lunell NO; Hjemdahl P; Fredholm BB; Nisell H; Persson B; Wager J
    Br J Clin Pharmacol; 1981 Sep; 12(3):345-8. PubMed ID: 7295464
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Rapid reduction of blood pressure with acute oral labetalol.
    Davies AB; Bala Subramanian V; Gould B; Raftery EB
    Br J Clin Pharmacol; 1982 May; 13(5):705-10. PubMed ID: 7082539
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.